Key Principles for Prescribing PrEP

(1) Persons who think they might have HIV infection, AIDS, or other STDs should not rely on anything in this website to self-diagnose or treat, but should instead consult their physician.

(2) Physicians should not consider this website to be a comprehensive tool for diagnosis or treatment of patients.

(3) The DOH has tried to present accurate information to assist patients and physicians in their determination whether PrEP can be beneficial for individual patient’s use, but makes no warranty about the accuracy or completeness of the information on this website.

  • PrEP should be prescribed as part of a comprehensive prevention plan in combination with condoms and risk reduction counseling, among other appropriate prevention tools including regular screenings for STDs
  • PrEP is indicated for HIV negative individuals who are at ongoing risk for acquiring HIV
  • PrEP may offer protection to HIV negative partners in sero-discordant relationships (where one partner is HIV positive and another partner is HIV negative) during attempts to conceive
  • Efficacy of PrEP is highly dependent on adherence
  • PrEP is contraindicated in individuals with documented HIV-infection or creatinine clearance <60 mL/min, and in those who are not ready to adhere to daily PrEP
  • The first prescription of PrEP should only be for 30 days
  • Regular patient visits and laboratory tests, at least every three months, are required to monitor HIV status, adherence and side effects
  • If patient presents with acute HIV infection, an HIV serologic screening test should be used in conjunction with a plasma HIV RNA assay
  • Discontinuation of PrEP should be immediate for patients who receive a reactive or positive HIV test result

Information derived from:

  1. Centers for Disease Control and Prevention. CDC, (2014).US Public Health Service Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014 A Clinical Practice Guideline. Retrieved from website: http://www.cdc.gov/hiv/pdf/PrEPguidelines2014.pdf
  2. Centers for Disease Control and Prevention. CDC, (2014).US Public Health Service Pre-Exposure Prophylaxis for the Prevention of HIV Infection in the United States – 2014 Clinical Providers’ Supplement. Retrieved from website: http://www.cdc.gov/hiv/pdf/PrEPProviderSupplement2014.pdf
  3. New York State Department of Health AIDS Institute. New York State Department of Health AIDS Institute (NYSDOH AI), (2014). Guidance for the Use of Pre-Exposure Prophylaxis (PrEP) To Prevent HIV Transmission. Retrieved from website: http://www.hivguidelines.org/wp-content/uploads/2015/03/PrEP-Guidance_3-27-15.pdf

Updated May, 2015